Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Portopulmonary hypertension in the current era of pulmonary hypertension management

Open access
Savale, Laurent, Guimas, Manuel, Ebstein, Nathan, Fertin, Marie, Jevnikar, Mitja, Renard, Sébastien, Horeau-Langlard, Delphine, Tromeur, Cécile, Chabanne, Céline, Prevot, Grégoire, Chaouat, Ari, Moceri, Pamela, Artaud-Macari, Élise, Degano, Bruno, Tresorier, Romain, Boissin, Clément, Bouvaist, Hélène, Simon, Anne-Claire, Riou, Marianne, Favrolt, Nicolas, Palat, Sylvain, Bourlier, Delphine, Magro, Pascal, Cottin, Vincent, Bergot, Emmanuel, Lamblin, Nicolas, Jaïs, Xavier, Coilly, Audrey, Durand, François, Francoz, Claire, Conti, Filomena, Hervé, Philippe, Simonneau, Gérald, Montani, David, Duclos-Vallée, Jean-Charles, Samuel, Didier, Humbert, Marc, De Groote, Pascal, Sitbon, Olivier · 2020 · Journal of Hepatology

Abstract

BACKGROUND & AIMS: Long-term outcomes in portopulmonary hypertension (PoPH) are poorly studied in the current era of pulmonary hypertension management. We analysed the effect of pulmonary arterial hypertension (PAH)-targeted therapies, survival and predictors of death in a large contemporary cohort of patients with PoPH. METHODS: Data from patients with PoPH consecutively enrolled in the French Pulmonary Hypertension Registry between 2007 and 2017 were collected. The effect of initial treatment strategies on functional class, exercise capacity and cardiopulmonary haemodynamics were analysed. Survival and its association with PAH- and hepatic-related characteristics were also examined. RESULTS: Six hundred and thirty-seven patients (mean age 55 ± 10 years; 58% male) were included. Fifty-seven percent had mild cirrhosis, i.e. Child-Pugh stage A. The median model for end-stage liver disease (MELD) score was 11 (IQR 9-15). Most patients (n = 474; 74%) were initiated on monotherapy, either with a phosphodiesterase-5 inhibitor (n = 336) or with an endothelin-receptor antagonist (n = 128); 95 (15%) were initiated on double oral combination therapy and 5 (1%) on triple therapy. After a median treatment time of 4.5 months, there were significant improvements in functional class (p <0.001), 6-minute walk distance (6MWD) (p <0.0001) and pulmonary vascular resistance (p <0.0001). Overall survival rates were 84%, 69% and 51% at 1, 3 and 5 years, respectively. Baseline 6MWD, sex, age and MELD score or Child-Pugh stage were identified as independent prognostic factors. Survival from PoPH diagnosis was significantly better in the subgroup of patients who underwent liver transplantation (92%, 83% and 81% at 1, 3 and 5 years, respectively). CONCLUSION: Survival of patients with PoPH is strongly associated with the severity of liver disease. Patients who underwent liver transplantation had the best long-term outcomes. LAY SUMMARY: Portopulmonary hypertension is defined by the presence of pulmonary arterial hypertension in the context of chronic liver disease and is characterized by progressive shortness of breath and exercise limitation. The presence of severe pulmonary arterial hypertension in liver transplant candidates represents a contraindication for such a surgery; however, treatments targeting pulmonary arterial hypertension are efficacious, allowing for safe transplantation and conferring good survival outcomes in those who undergo liver transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.02.021

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 170

Metadata

Authors
Savale, L., Guimas, M., Ebstein, N., Fertin, M., Jevnikar, M., Renard, S., Horeau-Langlard, D., Tromeur, C., Chabanne, C., Prevot, G., Chaouat, A., Moceri, P., Artaud-Macari, É., Degano, B., Tresorier, R., Boissin, C., Bouvaist, H., Simon, A.-C., Riou, M., Favrolt, N., Palat, S., Bourlier, D., Magro, P., Cottin, V., Bergot, E., Lamblin, N., Jaïs, X., Coilly, A., Durand, F., Francoz, C., Conti, F., Hervé, P., Simonneau, G., Montani, D., Duclos-Vallée, J.-C., Samuel, D., Humbert, M., De Groote, P., & Sitbon, O.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-07
Volume
73
Issue
1
Pages
130-139
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3010286720
Cited by
170
References
2
FWCI
12.07
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Portopulmonary hypertension in the current era of pulmonary hypertension management. https://app.cochat.ai/papers/10.1016/j.jhep.2020.02.021
The paper
Savale, L., Guimas, M., Ebstein, N., Fertin, M., Jevnikar, M., Renard, S., Horeau-Langlard, D., Tromeur, C., Chabanne, C., Prevot, G., Chaouat, A., Moceri, P., Artaud-Macari, É., Degano, B., Tresorier, R., Boissin, C., Bouvaist, H., Simon, A.-C., Riou, M., . . . Sitbon, O. (2020). Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.02.021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.